相似文献
1
Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'.
Nat Genet. 2019 Oct;51(10):1427-1428. doi: 10.1038/s41588-019-0509-5.
2
H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines.
Nat Genet. 2019 Oct;51(10):1426-1427. doi: 10.1038/s41588-019-0490-z.
3
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Endocr Relat Cancer. 2018 Mar;25(3):367-380. doi: 10.1530/ERC-17-0445.
4
KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model.
Neuroendocrinology. 2009;89(4):458-70. doi: 10.1159/000209330. Epub 2009 Mar 18.
5
Establishment and characterization of three novel cell lines - P-STS, L-STS, H-STS - derived from a human metastatic midgut carcinoid.
Anticancer Res. 2009 Jun;29(6):1951-61.
6
Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Pancreas. 2020 May/Jun;49(5):599-603. doi: 10.1097/MPA.0000000000001546.
7
Morfo-functional nutritional status in patients with gastroenteropancreatic neuroendocrine tumors (GEPNET).
Endocrinol Diabetes Nutr (Engl Ed). 2022 Aug-Sep;69(7):466-475. doi: 10.1016/j.endien.2022.07.007. Epub 2022 Aug 18.
8
The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment.
Cancer. 2010 Jun 15;116(12):2902-12. doi: 10.1002/cncr.25049.
9
Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Cancer. 2011 Sep 15;117(18):4141-54. doi: 10.1002/cncr.26011. Epub 2011 Mar 8.
10
Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1.
Surg Today. 2013 Mar;43(3):229-36. doi: 10.1007/s00595-012-0376-5. Epub 2012 Oct 19.
引用本文的文献
1
Multifaceted modeling of small intestinal neuroendocrine tumors.
Endocr Oncol. 2024 Nov 20;4(1):e240038. doi: 10.1530/EO-24-0038. eCollection 2024 Jan 1.
2
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Cancer Discov. 2023 Jun 2;13(6):1386-1407. doi: 10.1158/2159-8290.CD-22-1020.
3
Preclinical Models of Neuroendocrine Neoplasia.
Cancers (Basel). 2022 Nov 17;14(22):5646. doi: 10.3390/cancers14225646.
4
OncoLoop: A Network-Based Precision Cancer Medicine Framework.
Cancer Discov. 2023 Feb 6;13(2):386-409. doi: 10.1158/2159-8290.CD-22-0342.
5
A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection.
Commun Biol. 2022 Jul 19;5(1):714. doi: 10.1038/s42003-022-03663-8.
6
A Model for Network-Based Identification and Pharmacological Targeting of Aberrant, Replication-Permissive Transcriptional Programs Induced by Viral Infection.
Res Sq. 2022 Feb 4:rs.3.rs-1287631. doi: 10.21203/rs.3.rs-1287631/v1.
7
Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.
Neoplasia. 2021 Jan;23(1):80-98. doi: 10.1016/j.neo.2020.11.004. Epub 2020 Nov 25.
8
Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer.
Rev Endocr Metab Disord. 2021 Sep;22(3):495-510. doi: 10.1007/s11154-020-09607-z. Epub 2020 Oct 21.
本文引用的文献
1
H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines.
Nat Genet. 2019 Oct;51(10):1426-1427. doi: 10.1038/s41588-019-0490-z.
2
Establishment and characterization of three novel cell lines - P-STS, L-STS, H-STS - derived from a human metastatic midgut carcinoid.
Anticancer Res. 2009 Jun;29(6):1951-61.
Zotero 插件